ANTIVIRAL TYPE IIR FACEMASK

KILLS 99.99% OF SARS-COV-2 (COVID-19) AT JUST 10 MINUTES

proven to stop cross contamination

RAPID KILL innovation
Kills 99.99% of SARS-CoV-2 (COVID-19) at just
10 minutes
- + 8 hours Antiviral activity
Patented UK invention
- Uses “activated oxygen” driven by daylight
Unique NON-LEACHING technology
- The antiviral agent is bound to the mask
- No exposure to wearer or environment
Fully compliant Medical Device registered in the UK and EU

Previous work by university scientists highlight ways masks can be better:

Respiratory viruses (such as Influenza and coronaviruses) have been shown to collect on the outside of facemasks during wear
Coronavirus SARS-CoV-2 has been proven to survive on standard facemask for upto 7 days
Transfer (“cross contamination”) from masks has been demonstrated when they are removed
- Onto clothes and skin of the wearer

Independently validated. Positive impact demonstrated

Independent bespoke testing shows 99.99% kill of SARS-CoV-2 at 10 min
Have further in house and fully independent testing to ISO 18184 (to share)
Sanitas’ in house expertise allows further high impact experiments
Antiviral action proven for at least 8 hours (vs 1 hour standard test)
Kill of viral aerosols shown (vs standard large drops)
Crucially ZERO VIRAL TRANSFER from Protect AV mask when touched
- (100,000’s of infectious viruses moved from a standard mask)

Patents secured protecting our technology in a range of applications

Protect Type IIR Antiviral mask is a CE Marked Medical Device
MHRA Registered
Registered in the EU
Compliance with all required International Standards
- ISO10993 Biocompatibility
- EN14683 Blood Penetration, Filtration
- ISO14971 Medical Device Risk Management